Vasorelaxation effect and mechanism of action of vascular endothelial growth factor-165 in isolated perfused human skin flaps.

[1]  G. Gurtner,et al.  Vascular Delay Revisited , 2007, Plastic and reconstructive surgery.

[2]  A. Yim,et al.  Vasorelaxation induced by vascular endothelial growth factor in the human internal mammary artery and radial artery. , 2007, Vascular pharmacology.

[3]  C. Forrest,et al.  Efficacy and mechanism of adenovirus-mediated VEGF-165 gene therapy for augmentation of skin flap viability. , 2006, American journal of physiology. Heart and circulatory physiology.

[4]  C. Forrest,et al.  Acute local subcutaneous VEGF165 injection for augmentation of skin flap viability: efficacy and mechanism. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  F. Orlando,et al.  Local rh-VEGF administration enhances skin flap survival more than other types of rh-VEGF administration: a clinical, morphological and immunohistochemical study. , 2004, Experimental dermatology.

[6]  W. Mustain,et al.  Vascular Endothelium Growth Factor, Surgical Delay, and Skin Flap Survival , 2004, Annals of surgery.

[7]  K. Bley,et al.  Erratum to “Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists”: [Bioorg. Med. Chem. Lett. 14 (2004) 1053] , 2004 .

[8]  C. Forrest,et al.  Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature. , 2004, American journal of physiology. Heart and circulatory physiology.

[9]  K. Bley,et al.  Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists , 2004 .

[10]  W. Lineaweaver,et al.  Vascular endothelial growth factor (VEGF) expression and the effect of exogenous VEGF on survival of a random flap in the rat. , 2003, British journal of plastic surgery.

[11]  U. Bilkay,et al.  Improvement of TRAM Flap Viability Using Human VEGF-Induced Angiogenesis: A Comparative Study of Delay Techniques , 2003, Plastic and reconstructive surgery.

[12]  K. Shigenobu,et al.  Phospholipase C inhibitors suppress spontaneous mechanical activity of guinea pig urinary bladder smooth muscle. , 2003, Biological & pharmaceutical bulletin.

[13]  A. D. de Vos,et al.  KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF , 2002, Hypertension.

[14]  C. Forrest,et al.  Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[15]  R. Bolli,et al.  Biphasic response of cardiac NO synthase isoforms to ischemic preconditioning in conscious rabbits. , 2000, American journal of physiology. Heart and circulatory physiology.

[16]  W. Lineaweaver,et al.  The effects of VEGF on survival of a random flap in the rat: examination of various routes of administration. , 2000, British journal of plastic surgery.

[17]  D. Y. Lee,et al.  Vascular Endothelial Growth Factor Governs Endothelial Nitric-oxide Synthase Expression via a KDR/Flk-1 Receptor and a Protein Kinase C Signaling Pathway* , 1999, The Journal of Biological Chemistry.

[18]  M. Marrero,et al.  Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-Src* , 1999, The Journal of Biological Chemistry.

[19]  L. L. Pu,et al.  Endothelial cell growth factor enhances musculocutaneous flap survival through the process of neovascularization. , 1999, Annals of plastic surgery.

[20]  J. Lipa,et al.  Vasoconstrictor effect of endothelin-1 in human skin: role of ETA and ETB receptors. , 1999, American journal of physiology. Heart and circulatory physiology.

[21]  G. Angelini,et al.  Nitric oxide, prostacyclin and cyclic nucleotide formation in externally stented porcine vein grafts. , 1998, Atherosclerosis.

[22]  William E. Schweinle,et al.  The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat , 1998, Psychopharmacology.

[23]  I. Koshima,et al.  Paraumbilical perforator flap without deep inferior epigastric vessels. , 1998 .

[24]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. , 1998, Circulation.

[25]  I. Zachary,et al.  Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinase , 1997, FEBS letters.

[26]  M. Marletta,et al.  Potent and selective inhibition of neuronal nitric oxide synthase by N(ω)-propyl-L-arginine , 1997 .

[27]  K. Mikoshiba,et al.  2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release. , 1997, Journal of biochemistry.

[28]  Richard Graham Knowles,et al.  1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.

[29]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. , 1997, Circulation.

[30]  E. Browne,et al.  Effect of Vascular Endothelial Growth Factor (VEGF) on Survival of Random Extension of Axial Pattern Skin Flaps in the Rat , 1996, Annals of plastic surgery.

[31]  J. Flanagan,et al.  Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.

[32]  J. Hanke,et al.  Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor , 1996, The Journal of Biological Chemistry.

[33]  C. Forrest,et al.  Vascular effects and mechanism of action of endothelin-1 in isolated perfused pig skin. , 1995, Journal of applied physiology.

[34]  J. Roberts,et al.  Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. , 1995, Circulation research.

[35]  D. Breuer,et al.  Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. , 1994, The Journal of pharmacology and experimental therapeutics.

[36]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[37]  C. Pang,et al.  Evidence for endothelium-dependent and endothelium-independent vasodilation in human skin flaps. , 1992, Canadian journal of physiology and pharmacology.

[38]  I. Koshima,et al.  Free Thin Paraumbilical Perforator‐based Flaps , 1992, Annals of plastic surgery.

[39]  C. Pang,et al.  The isolated perfused human skin flap: design, perfusion technique, metabolism, and vascular reactivity. , 1991, Plastic and reconstructive surgery.

[40]  J. Herbert,et al.  Chelerythrine is a potent and specific inhibitor of protein kinase C. , 1990, Biochemical and biophysical research communications.

[41]  C. Kerrigan,et al.  Dermofluorometry: thresholds for predicting flap survival. , 1989, Plastic and reconstructive surgery.

[42]  C. Forrest,et al.  Pharmacological Augmentation of Skin Flap Viability: A Hypothesis to Mimic the Surgical Delay Phenomenon or a Wishful Thought , 1989, Annals of plastic surgery.

[43]  P. D. Watson.  Colloid osmotic pressure changes in isolated isogravimetric cat hindlimb. , 1982, American Journal of Physiology.

[44]  R Y Tsien,et al.  New calcium indicators and buffers with high selectivity against magnesium and protons: design, synthesis, and properties of prototype structures. , 1980, Biochemistry.

[45]  A. Avolio,et al.  Plasma protein concentration and control of coronary vascular resistance in isolated rat heart. , 1980, The American journal of physiology.

[46]  David D Roberts,et al.  Nitric oxide in wound‐healing , 2005, Microsurgery.